160 related articles for article (PubMed ID: 27599913)
1. Efficacy and safety of bilastine in Japanese patients with chronic spontaneous urticaria: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study.
Hide M; Yagami A; Togawa M; Saito A; Furue M
Allergol Int; 2017 Apr; 66(2):317-325. PubMed ID: 27599913
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Bilastine on Symptoms of Allergic Rhinitis and Chronic Urticaria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Abdelshafy AM; Abdallah SY; Hassan AF; Mohamed HA; Kamal NM; Ali ST; Abdelhaleem IA
Am J Rhinol Allergy; 2022 Sep; 36(5):684-694. PubMed ID: 35593100
[TBL] [Abstract][Full Text] [Related]
3. Bilastine 0.6% Preservative-free Eye Drops: A Once-daily Treatment for Allergic Conjunctivitis.
Gomes PJ; Ciolino JB; Arranz P; Hernández G; Fernández N
J Investig Allergol Clin Immunol; 2024 Jun; 34(3):167-176. PubMed ID: 36811846
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bilastine vs. levocetirizine for the treatment of chronic idiopathic urticaria: A multicenter, double-blind, double-dummy, phase III, non-inferiority, randomized clinical trial.
Chen X; Han X; Cheng B; Li H; Liu L; Geng S; Li L; Li J; Guo Q; Zhang G; Fang H; Zhang J
Chin Med J (Engl); 2024 Jun; 137(12):1480-1482. PubMed ID: 38557589
[No Abstract] [Full Text] [Related]
5. An international Delphi study on the burden of allergic rhinoconjunctivitis and urticaria and the role of bilastine among current treatment options.
Church MK; Canonica GW; Kuna P; Maurer M; Mösges R; Novak Z; Papadopoulos NG; Rodriguez Del Rio P;
Expert Rev Clin Immunol; 2023; 19(7):813-820. PubMed ID: 37191185
[TBL] [Abstract][Full Text] [Related]
6. Targeting histamine receptor 4 in cholinergic urticaria with izuforant (LEO 152020): results from a phase IIa randomized double-blind placebo-controlled multicentre crossover trial.
Grekowitz E; Metz M; Altrichter S; Bauer A; Brockow K; Heine G; Lionnet L; Saday KK; Hultsch T; Søerensen OE; Maurer M
Br J Dermatol; 2024 May; 190(6):825-835. PubMed ID: 38308655
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M; Ensina LF; Gimenez-Arnau AM; Sussman G; Hide M; Saini S; Grattan C; Fomina D; Rigopoulos D; Berard F; Canonica GW; Rockmann H; Irani C; Szepietowski JC; Leflein J; Bernstein JA; Peter JG; Kulthanan K; Godse K; Ardusso L; Ukhanova O; Staubach P; Sinclair R; Gogate S; Thomsen SF; Tanus T; Ye YM; Burciu A; Barve A; Modi D; Scosyrev E; Hua E; Letzelter K; Varanasi V; Patekar M; Severin T;
Lancet; 2024 Jan; 403(10422):147-159. PubMed ID: 38008109
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Once-Daily Ophthalmic Bilastine for the Treatment of Allergic Conjunctivitis: A Dose-Finding Study.
Gomes PJ; Ciolino JB; Arranz P; Hernández G; Fernández N
J Investig Allergol Clin Immunol; 2023 Jul; 33(4):271-280. PubMed ID: 35234641
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of fixed-dose combination of Bilastine-Montelukast in adult patients with allergic rhinitis: a phase III, randomized, multi-center, double-blind, active controlled clinical study.
Sinha SD; Perapogu S; Chary S S; Ramesh S; Bakshi J; Singh A; Ahmed AK; Mohan Reddy B; Panapakam M; Talluri L; Vattipalli R
J Asthma; 2023 Nov; 60(11):2014-2020. PubMed ID: 37140964
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of efficacy and safety of cetirizine and bilastine in patients of chronic spontaneous urticaria: Open-label, randomized, parallel-group study.
Sinha VV; Kalikar MV; Mukhi JI; Giradkar AB; Sontakke S
Perspect Clin Res; 2023; 14(4):180-186. PubMed ID: 38025284
[TBL] [Abstract][Full Text] [Related]
11. A Comparative, Three-Arm, Randomized Clinical Trial to Evaluate the Effectiveness and Tolerability of Bilastine vs Fexofenadine vs Levocetirizine at the Standard Dose and Bilastine vs Fexofenadine at Higher Than the Standard Dose (Up-Dosing) vs Levocetirizine and Hydroxyzine (in Combination) in Patients with Chronic Spontaneous Urticaria.
Shah B; Dhoot D; Choudhary A; Jangid N; Mistry D; Shah S; Kamat S; Barkate H
Clin Cosmet Investig Dermatol; 2022; 15():261-270. PubMed ID: 35221703
[TBL] [Abstract][Full Text] [Related]
12. Double-blind placebo-controlled trial of dapsone in antihistamine refractory chronic idiopathic urticaria.
Morgan M; Cooke A; Rogers L; Adams-Huet B; Khan DA
J Allergy Clin Immunol Pract; 2014; 2(5):601-6. PubMed ID: 25213055
[TBL] [Abstract][Full Text] [Related]
13. Bilastine in Refractory Chronic Spontaneous Urticaria: Disease Control and Cytokine Modulation in an Open-label Prospective Study.
De A; Singh S; Chakraborty D; Sarda A; Godse K
Indian J Dermatol; 2024; 69(2):132-136. PubMed ID: 38841225
[TBL] [Abstract][Full Text] [Related]
14. Effect of Bilastine on Chronic Urticaria: A Systematic Review and Meta-Analysis.
Xue X; Wang Q; Yang X; Tu H; Deng Z; Kong D; Liu W; Fan Z; Li N
Int Arch Allergy Immunol; 2023; 184(2):176-185. PubMed ID: 36380619
[TBL] [Abstract][Full Text] [Related]
15. Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study.
Kuna P; Jutel M; Pulka G; Tokarski S; Arranz P; Hernández G; Fernández Hernando N
Clin Ophthalmol; 2023; 17():735-746. PubMed ID: 36909350
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical Trial.
Majorek-Olechowska B; Slomskis T; Zollerová L; Martín I; Sánchez C; Gilaberte I; Arranz P;
J Investig Allergol Clin Immunol; 2024 May; ():0. PubMed ID: 38725318
[TBL] [Abstract][Full Text] [Related]
17. Real-World Indian Experience of Switchover to Bilastine 40 mg/day in CSU Patient Refractory to Other Antihistamines at Double Dose.
De A; Shah B; Banodkar PD; Dhoot D; Chitnis K; Barkate H
Indian J Dermatol; 2023; 68(6):674-677. PubMed ID: 38371575
[TBL] [Abstract][Full Text] [Related]
18. Experience with bilastine in the management of urticaria: Original Real-world cases of Bilastine In Treatment (ORBIT) in Asia.
Cheong WK; Chan AWM; Ch'ng CC; Chung WH; Gabriel MT; Godse K; Mitthamsiri W; Nguyen HT; Tiongco-Recto M; Nagrale D
Drugs Context; 2022; 11():. PubMed ID: 35371270
[TBL] [Abstract][Full Text] [Related]
19. Comparative study on the efficacy and safety of bepotastine besilate versus levocetirizine in chronic spontaneous urticaria: A randomised, open-label, parallel study.
Gayathri E; Sowmya P; Punnagai K; Mahalakshmi V
Indian J Dermatol Venereol Leprol; 2023; 89(5):672-679. PubMed ID: 37067147
[TBL] [Abstract][Full Text] [Related]
20. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria.
Maurer M; Berger W; Giménez-Arnau A; Hayama K; Jain V; Reich A; Haemmerle S; Lheritier K; Walsh P; Xia S; Storim J
J Allergy Clin Immunol; 2022 Dec; 150(6):1498-1506.e2. PubMed ID: 36096203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
